South American Thoracic Stent-Graft Study
Launched by TRIVASCULAR, INC. · Mar 5, 2010
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * The TriVascular Thoracic Stent Graft System is indicated in subjects diagnosed with an aneurysm in the descending thoracic aorta having vascular morphology suitable for endovascular repair, including:
- • Adequate iliac/femoral access compatible with the required delivery systems,
- • Non-aneurysmal aortic segments proximal and distal to the aneurysm.
About Trivascular, Inc.
Trivascular, Inc. is a leading medical device company specializing in the development and commercialization of innovative vascular solutions. Focused on advancing endovascular therapies, Trivascular is dedicated to improving patient outcomes through cutting-edge technologies that address complex vascular diseases. With a commitment to clinical excellence and rigorous research, the company collaborates with healthcare professionals to enhance procedural efficiency and effectiveness. Trivascular’s pioneering approach aims to transform the landscape of vascular treatment, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago, , Chile
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials